Literature DB >> 642793

Randomized trial of protected environment--prophylactic antibiotics in 145 adults with acute leukemia.

V Rodriguez, G P Bodey, E J Freireich, K B McCredie, J U Gutterman, M J Keating, T L Smith, E A Gehan.   

Abstract

One hundred and forty-five adults with acute leukemia were randomized to receive remission induction therapy in or out of a protected environment (PE) with prophylactic antibiotics orally (PA) or systemically (SA). Sixty-three patients were randomized in PE and 82 outside a PE. The proportion of patients who survived long enough to receive an adequate trial was higher in the PE (97%) than out (82%) (P = .01). The complete remission (CR) rate was 71% in and 43% out of the PE (P less than .01). Fifty-five patients received PA and 90 received SA. The CR rates were 61% and 45%, respectively. Of the 145 patients, 73 (50%) developed 102 episodes of major infections. Twenty-six of 63 patients in the PE developed major infection compared to 47 of 82 outside a PE (P = .08). The incidence rate of 13% fatal infections in a PE was significantly smaller than the 28% rate outside a PE (P = .04). The number of days with infections at less than 500 neutrophils/mm3 was also significantly lower inside a PE than outside (P less than .01). When comparing patients receiving SA or PA, there was no statistically significant difference in the incidence of infections. Forty-one patients received OAP Chemotherapy and 104 received adriamycin-OAP plus BCG. The CR rate on OAP was 44% compared with 60% on Ad-OAP + BCG. Infection rates were 76% and 40%, respectively (P less than .01). The median survival time was 72 weeks for patients in PE compared with 42 weeks for patients outside a PE (P less than .01). The prophylactic antibiotic regimens were well tolerated by most patients. This prospective randomized study has demonstrated statistically significant advantages for a lowered risk of fatal infection, higher CR rate and longer survival of patients treated in a PE with prophylactic antibiotics compared with patients treated in a conventional hospital room. Also, there was evidence for the superiority of adriamycin-OAP + BCG treatment compared with OAP.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 642793     DOI: 10.1097/00005792-197805000-00005

Source DB:  PubMed          Journal:  Medicine (Baltimore)        ISSN: 0025-7974            Impact factor:   1.889


  21 in total

1.  Infection prophylaxis in neutropenic patients-a controversial subject.

Authors:  G P Bodey
Journal:  West J Med       Date:  1983-05

2.  Prevention of infection and graft-versus-host disease by suppression of intestinal microflora in children treated with allogeneic bone marrow transplantation.

Authors:  J M Vossen; P J Heidt; H van den Berg; E J Gerritsen; J Hermans; L J Dooren
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-01       Impact factor: 3.267

3.  Laminar air flow isolation and decontamination: a prospective randomized study of the effects of prophylactic systemic antibiotics in bone marrow transplant patients.

Authors:  F B Petersen; C D Buckner; R A Clift; S Lee; N Nelson; G W Counts; J D Meyers; J E Sanders; P S Stewart; W I Bensinger
Journal:  Infection       Date:  1986 May-Jun       Impact factor: 3.553

4.  The concept of immunochemosurgery in gastric cancer.

Authors:  J P Kim
Journal:  World J Surg       Date:  1987-08       Impact factor: 3.352

5.  Prolonged granulocytopenia due to selective antimicrobial modulation of the intestinal flora of irradiated mice: the impact on recovery from infection.

Authors:  H F Guiot; E F Tordoir-van der Bent; A V Helmig-Schurter
Journal:  Infection       Date:  1988 May-Jun       Impact factor: 3.553

6.  Effect of systemic antimicrobial prophylaxis on microbial flora.

Authors:  G P Bodey; B Rosenbaum; M Valdivieso; R Bolivar
Journal:  Antimicrob Agents Chemother       Date:  1982-03       Impact factor: 5.191

7.  [Prevention of infection during induction therapy in acute leukemia].

Authors:  E Kurrle
Journal:  Klin Wochenschr       Date:  1981-10-01

8.  Preventing infection in neutropenic cancer patients.

Authors:  S M Beutler; N M Barth; A S Bayer
Journal:  West J Med       Date:  1983-05

9.  Prophylactic non-absorbable antibiotics in leukaemic patients.

Authors:  K King
Journal:  J Hyg (Lond)       Date:  1980-08

10.  Iatrogenic and idiopathic acute myelogenous leukemia: a comparison of clinical features and treatment complications.

Authors:  C K Williams; J Cuttner; T Ohnuma; E P Ambinder; P P Ferreira; J F Holland
Journal:  Med Oncol Tumor Pharmacother       Date:  1987
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.